Reference is made to the announcement by IDEX Biometrics ASA (the "Company") on 29 April 2026, regarding the completion of a private placement of 9,696,969 shares at NOK 8.25 per share into two tranches (the "April 2026 Private Placement"). Reference is further made to the stock exchange announcement made by the Company on 29 May 2026 regarding the completion of a private placement of 2,500,000 shares at NOK 8.25 per share (the "May 2026 Private Placement").
Following the approval and publication of the listing prospectus, as announced in the stock exchange announcement on 15 June 2026, 6,607,910 shares, whereof 812,137 shares are pertaining to tranche 1 of the April 2026 Private Placement, 3,295,773 shares are pertaining to tranche 2 of the April 2026 Private Placement and 2,500,000 shares are pertaining to the May 2026 Private Placement, have been redelivered to Anders Storbråten, the chair of the board of directors of the Company (the "Share Lender") pursuant to the share lending agreements as described in the stock exchange announcements on 29 April 2026 and 29 May 2026.
Notification of the redelivery of shares in accordance with the Market Abuse Regulation article 19 is attached to this announcement.
Following the redelivery of borrowed shares, the Share Lender's holding of 5,727,605 ordinary shares in the Company (of which 3,850,973 ordinary shares is held directly, and 1,876,632 shares is held through Pinchcliffe AS), will be increased to 12,335,515 ordinary shares in the Company, constituting respectively approximately 7.4% and approximately 15.96% of the share capital and votes outstanding in the Company. Consequently, the Share Lender's total registered holding of shares will cross above the 10% and 15% thresholds pursuant to section 4-2 (1) of the Norwegian Securities Trading Act. The above calculations have been made based on a total of 77,308,932 outstanding shares in the Company currently registered in the Norwegian Register of Business Enterprises (the "NRBE").
This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation Article 19 and section 4-2 and section 5-12 of the Norwegian Securities Trading Act.